Zejing Pharmaceutical (688266.SH) signed an exclusive market promotion service agreement for injectable recombinant human thyrotropin.

Financial Information News App, Zejing Pharmaceutical (688266.SH) announced that the company signed a "Service Agreement" with ATSA, a Swiss subsidiary of Merck KGaA, on June 5, 2025. The company has agreed to authorize ATSA as the exclusive marketing service provider for the injection of recombinant human thyroid stimulating hormone in mainland China.